AR104113A1 - PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - Google Patents
PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORSInfo
- Publication number
- AR104113A1 AR104113A1 ARP160100818A ARP160100818A AR104113A1 AR 104113 A1 AR104113 A1 AR 104113A1 AR P160100818 A ARP160100818 A AR P160100818A AR P160100818 A ARP160100818 A AR P160100818A AR 104113 A1 AR104113 A1 AR 104113A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- peptide
- cells
- peptides
- patient
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 13
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 238000000034 method Methods 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 108091023037 Aptamer Proteins 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229940038309 personalized vaccine Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un péptido caracterizado porque comprende una secuencia de aminoácidos que se elige del grupo que consiste en SEQ ID Nº 1 a SEQ ID Nº 288, y secuencias variantes de las mismas que son por lo menos 88% homólogas a SEQ ID Nº 1 a SEQ ID Nº 288, y en donde dicha variante se une a molécula(s) del complejo mayor de histocompatibilidad (MHC) y/o induce a las células T para reaccionar en forma cruzada con dicho péptido variante; y una sal farmacéuticamente aceptable de la misma, en donde dicho péptido no es un polipéptido de longitud completa. Reivindicación 12: Un método in vitro para producir linfocitos T activados, caracterizado porque el método comprende poner en contacto in vitro las células T con moléculas MHC de clase I o Il humanas cargadas con antígeno expresadas sobre la superficie de una célula presentadora de antígeno adecuada o una construcción artificial que imita a una célula presentadora de antígeno durante un periodo de tiempo suficiente para activar dichas células T de una forma específica de antígeno, en donde dicho antígeno es un péptido de acuerdo con cualquiera de las reivindicaciones 1 a 4. Reivindicación 14: Un método para matar células blanco en un paciente en donde las células blanco presentan un polipéptido que comprende una secuencia de aminoácidos dada en cualquiera de las reivindicaciones 1 a 4, caracterizado porque el método comprende administrar al paciente una cantidad eficaz de células T activadas como se define en la reivindicación 13. Reivindicación 21: Un método para producir una vacuna anticáncer personalizada, caracterizado porque dicho método comprende: a) identificar los péptidos asociados a tumor (TUMAP) presentados por una muestra tumoral a partir de dicho paciente individual; b) comparar los péptidos identificados en a) con un depósito de péptidos que se han precribado para inmunogenicidad y/o sobre presentación en tumores, en comparación con tejidos normales; c) seleccionar por lo menos un péptido a partir de un depósito que coincide con un TUMAP identificado en el paciente; y d) formular la vacuna personalizada en base al paso c). Reivindicación 31: El receptor de células T de acuerdo con la reivindicación 30, caracterizado porque dicha secuencia de aminoácidos es por lo menos 88% idéntica a la SEQ ID Nº 1 a SEQ ID Nº 288. Reivindicación 39: Una composición farmacéutica caracterizada porque comprende por lo menos un ingrediente activo que se elige del grupo que consiste en el péptido de acuerdo con cualquiera de las reivindicaciones 1 a 6, el ácido nucleico de acuerdo con la reivindicación 7, el vector de expresión de acuerdo con la reivindicación 8, la célula de acuerdo con la reivindicación 9, el linfocito T activado de acuerdo con la reivindicación 13 o el anticuerpo de acuerdo con la reivindicación 15 o receptor de células T de acuerdo con cualquiera de las reivindicaciones 30 a 32 o el aptámero de acuerdo con la reivindicación 38, y un transportador farmacéuticamente aceptable, y opcionalmente excipientes y/o estabilizantes adicionales farmacéuticamente aceptables.Claim 1: A peptide characterized in that it comprises an amino acid sequence that is chosen from the group consisting of SEQ ID No. 1 to SEQ ID No. 288, and variant sequences thereof that are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 288, and wherein said variant binds to molecule (s) of the major histocompatibility complex (MHC) and / or induces T cells to cross-react with said variant peptide; and a pharmaceutically acceptable salt thereof, wherein said peptide is not a full length polypeptide. Claim 12: An in vitro method for producing activated T lymphocytes, characterized in that the method comprises contacting in vitro T cells with human MHC class I or Il molecules loaded with antigen expressed on the surface of a suitable antigen presenting cell or an artificial construction that mimics an antigen presenting cell for a period of time sufficient to activate said T cells of a specific form of antigen, wherein said antigen is a peptide according to any one of claims 1 to 4. Claim 14: A method for killing white cells in a patient wherein the white cells have a polypeptide comprising an amino acid sequence given in any one of claims 1 to 4, characterized in that the method comprises administering to the patient an effective amount of activated T cells as defined in claim 13. Claim 21: A method to produce a personalized anti-cancer vaccine, characterized in that said method comprises: a) identifying tumor associated peptides (TUMAP) presented by a tumor sample from said individual patient; b) compare the peptides identified in a) with a deposit of peptides that have been prescribed for immunogenicity and / or on presentation in tumors, compared to normal tissues; c) select at least one peptide from a reservoir that matches a TUMAP identified in the patient; and d) formulate the personalized vaccine based on step c). Claim 31: The T-cell receptor according to claim 30, characterized in that said amino acid sequence is at least 88% identical to SEQ ID No. 1 to SEQ ID No. 288. Claim 39: A pharmaceutical composition characterized in that it comprises at least one active ingredient that is chosen from the group consisting of the peptide according to any one of claims 1 to 6, the nucleic acid according to claim 7, the expression vector according to claim 8, the cell of according to claim 9, the activated T lymphocyte according to claim 13 or the antibody according to claim 15 or T cell receptor according to any of claims 30 to 32 or the aptamer according to claim 38, and a pharmaceutically acceptable carrier, and optionally additional pharmaceutically acceptable excipients and / or stabilizers.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139189P | 2015-03-27 | 2015-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104113A1 true AR104113A1 (en) | 2017-06-28 |
Family
ID=59256464
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100818A AR104113A1 (en) | 2015-03-27 | 2016-03-28 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP180102260A AR112781A2 (en) | 2015-03-27 | 2018-08-08 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100945A AR121809A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100947A AR121810A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102260A AR112781A2 (en) | 2015-03-27 | 2018-08-08 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS |
| ARP210100949A AR121812A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100945A AR121809A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100947A AR121810A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210100948A AR121811A2 (en) | 2015-03-27 | 2021-04-09 | PEPTIDE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-LYMPHOCYTE, ANTIBODY, T-CELL RECEPTOR, PHARMACEUTICAL COMPOSITION, KIT AND RELATED METHODS |
| ARP210102531A AR123493A2 (en) | 2015-03-27 | 2021-09-13 | PEPTIDE, NUCLEIC ACID, EXPRESSION VECTOR, RECOMBINANT HOST CELL, ANTIBODY, KIT, PHARMACEUTICAL COMPOSITION AND RELATED METHODS |
Country Status (1)
| Country | Link |
|---|---|
| AR (7) | AR104113A1 (en) |
-
2016
- 2016-03-28 AR ARP160100818A patent/AR104113A1/en not_active Application Discontinuation
-
2018
- 2018-08-08 AR ARP180102260A patent/AR112781A2/en not_active Application Discontinuation
-
2021
- 2021-04-09 AR ARP210100949A patent/AR121812A2/en not_active Application Discontinuation
- 2021-04-09 AR ARP210100945A patent/AR121809A2/en not_active Application Discontinuation
- 2021-04-09 AR ARP210100947A patent/AR121810A2/en not_active Application Discontinuation
- 2021-04-09 AR ARP210100948A patent/AR121811A2/en not_active Application Discontinuation
- 2021-09-13 AR ARP210102531A patent/AR123493A2/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR123493A2 (en) | 2022-12-07 |
| AR121811A2 (en) | 2022-07-13 |
| AR121812A2 (en) | 2022-07-13 |
| AR121809A2 (en) | 2022-07-13 |
| AR112781A2 (en) | 2019-12-11 |
| AR121810A2 (en) | 2022-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127116A2 (en) | NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | |
| AR106920A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) AND OTHER TYPES OF CANCER | |
| AR105817A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER TYPES OF CANCER | |
| AR108035A1 (en) | TREATMENTS AGAINST UTERUS CANCER | |
| ES2387685T3 (en) | Peptide WT1 restricted by HLA-A * 3303 and pharmaceutical composition comprising the same | |
| CY1123526T1 (en) | INNOVATIVE IMMUNOTHERAPY AGAINST VARIOUS TUMORS INCLUDING NEURON AND BRAIN TUMORS | |
| CL2019003423A1 (en) | New peptides (seq id no 378), combinations of peptides and carriers for use in the immunotherapeutic treatment of various types of cancer. (divisional request 201800545) | |
| PE20240645A1 (en) | IMMUNOGENIC PEPTIDE DERIVED FROM HUMAN LEUKOCYTE ANTIGEN (HLA) MOLECULES AS A BIOMARKER IN THE IMMUNOTHERAPY OF VARIOUS TUMORS | |
| EA201892021A1 (en) | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE OF CANCER DISEASES IN IMMUNOTHERAPY | |
| EA201891759A1 (en) | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE OF CANCER DISEASES IN IMMUNOTHERAPY | |
| MX364370B (en) | PERSONALIZED CANCER VACCINES AND ADOPTIVE IMMUNE CELL THERAPIES. | |
| PE20181316A1 (en) | NEW PEPTIDES AND PEPTIDE COMBINATION FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TYPES OF CANCER | |
| EA201791150A1 (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE USE OF HEPATOCULAR CARCINOMY (HCC) AND OTHER CANCER TYPES IN IMMUNOTHERAPY | |
| RU2013131089A (en) | TEM8 PEPTIDES AND THEIR VACCINES CONTAINING THEM | |
| CY1117115T1 (en) | Innovative Immunotherapy Against Tumors And Neurons Of The Brain | |
| AR110857A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER TYPES OF CANCER | |
| JP2023036860A (en) | Methods of generating populations of tumour-infiltrating t cells | |
| ES3009108T3 (en) | Hla-b57 open conformers | |
| AR104113A1 (en) | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | |
| AR114737A1 (en) | IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO A * 01 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS | |
| AR108092A1 (en) | PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ACUTE MYELOID LEUKEMIA (LMA) AND OTHER TYPES OF CANCER | |
| AR105851A1 (en) | PEPTIDES, COMBINATIONS OF PEPTIDES AND SUPPORTS FOR USE IN THE IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS TYPES OF CANCER | |
| AR122594A2 (en) | PEPTIDE, FUSION PROTEIN, T-CELL RECEPTOR, NUCLEIC ACID MOLECULE, EXPRESSION VECTOR, HOST CELL, ACTIVATED T-CELL, KIT, COMPOSITION, AND RELATED METHODS | |
| AR115643A1 (en) | PEPTIDES RESTRICTED BY A * 03 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS | |
| ES2734561T3 (en) | Cell Penetration Peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |